27 November 2020>: Clinical Research
The Safety and Efficacy of Apatinib Treatment in Addition to Concurrent Chemoradiotherapy in Patients with Nonoperative Locally Advanced Esophageal Squamous Cell Carcinoma
Lijun Hu 1ABCDEF , Ze Kong 1BCDF , Qinghong Meng 1BCD , Jianlin Wang 1BCF , Mengyun Zhou 1BC , Jingping Yu 1ACEG* , Xiaodong Jiang 2ACEG*DOI: 10.12659/MSM.927221
Med Sci Monit 2020; 26:e927221
Figure 4 Comparison of progression-free survival (PFS) between the chemoradiotherapy plus Apatinib (Apatinib) group and the concurrent chemoradiotherapy only (CCRT) group. Group 1: Apatinib group; Group 0: CCRT group.